# MTHFR Gene Mutations (C677T & A1298C): Enzymatic Function, Homocysteine Metabolism, and Diagnostic Evidence
## Key Takeaways
- The MTHFR gene encodes a critical enzyme in folate metabolism, catalyzing the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary methyl donor for homocysteine remethylation.
- The common C677T (Ala222Val) and A1298C (Glu429Ala) polymorphisms lead to reduced enzymatic activity, with C677T causing thermolability and A1298C affecting regulatory domain function.
- Reduced MTHFR activity can result in hyperhomocysteinemia, a risk factor for venous thromboembolism, recurrent pregnancy loss, neural tube defects, and cardiovascular disease, with clinical significance influenced by folate status and gene-environment interactions.
- Diagnostic evidence links MTHFR variants to various clinical phenotypes, and genetic testing, often via PCR-RFLP or real-time PCR, is used to assess risk, particularly in cases of unexplained thrombosis or recurrent pregnancy loss.
- Pharmacological interventions include L-methylfolate supplementation to bypass the MTHFR enzymatic block, and co-factor support with B vitamins (B12, B6, riboflavin), which can help mitigate the metabolic consequences of MTHFR variants.
- MTHFR variants can influence the efficacy and toxicity of certain drugs, notably methotrexate, and may interact with host genetic factors to modulate susceptibility to infectious diseases like COVID-19 and Hepatitis B.
---
## Executive Summary & Key Metadata
The **5,10-methylenetetrahydrofolate reductase (MTHFR)** gene encodes a critical enzyme in folate metabolism, catalyzing the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the primary circulating form of folate and the methyl donor for homocysteine remethylation to methionine. This reaction is the rate-limiting step in the folate cycle and is essential for maintaining cellular methylation capacity, DNA synthesis, and redox homeostasis. The two most extensively studied single-nucleotide polymorphisms (SNPs), **C677T (rs1801133)** and **A1298C (rs1801131)**, result in reduced enzymatic activity and have been implicated in a broad spectrum of clinical phenotypes, including hyperhomocysteinemia, venous thromboembolism, recurrent pregnancy loss, neural tube defects, cardiovascular disease, and various malignancies [1][2][1][2][1][2][1][2][1][2].
| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | MTHFR |
| **UniProt Accession** | P42898 |
| **Representative PDB ID** | 6FCX |
| **Chromosomal Locus** | 1p36.22 |
| **Primary Molecular Function** | Catalyzes conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate; FAD and NADPH-dependent oxidoreductase |
| **Disease & Pathology Associations** | Hyperhomocysteinemia, neural tube defects, recurrent pregnancy loss, venous thromboembolism, cardiovascular disease, diabetic nephropathy, certain cancers, migraine with aura, psychiatric disorders |
The clinical significance of MTHFR variants is context-dependent, influenced by folate status, ethnic background, and gene-environment interactions. This reference manual provides a comprehensive, biophysically detailed analysis of the MTHFR gene, its protein product, and the diagnostic evidence linking its common polymorphisms to human disease.
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Gene Structure
The MTHFR gene is located on the short arm of chromosome 1 at cytogenetic band **1p36.22**, a gene-dense region associated with several developmental and metabolic disorders. The gene spans approximately **20.4 kilobases (kb)** of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the chromosome. The genomic coordinates (GRCh38/hg38 assembly) are approximately **chr1:11,785,723–11,805,970**.
The gene comprises **11 exons** and **10 introns**, with the coding sequence distributed across exons 1 through 11. Exon 1 contains the 5' untranslated region (5' UTR) and the translation initiation codon, while exon 11 contains the termination codon and a long 3' UTR that includes multiple polyadenylation signals and regulatory elements. The intronic regions vary considerably in size, with intron 1 being the largest at approximately 4.5 kb, containing several regulatory elements including promoter-proximal sequences and potential enhancer regions.
### 1.2 Promoter Architecture and Transcription Factor Binding
The MTHFR promoter region lacks a canonical TATA box but contains a high GC content, characteristic of housekeeping gene promoters. Multiple **Sp1 (Specificity Protein 1)** binding sites are present within the proximal promoter, which are essential for basal transcriptional activity. Additional transcription factor binding sites identified through chromatin immunoprecipitation (ChIP) and reporter assays include:
- **CREB (cAMP response element-binding protein)**: Binds to cAMP response elements (CRE) in the promoter, linking MTHFR expression to cellular energy status and hormonal signaling.
- **NF-κB (Nuclear Factor kappa B)**: Response elements for NF-κB are present, suggesting inflammatory regulation of MTHFR transcription.
- **PPARγ (Peroxisome Proliferator-Activated Receptor Gamma)**: Binding sites for this nuclear receptor have been identified, potentially linking folate metabolism to lipid homeostasis.
- **HIF-1α (Hypoxia-Inducible Factor 1 Alpha)**: Hypoxia-responsive elements in the promoter region may modulate MTHFR expression under low-oxygen conditions.
The promoter also contains **CpG islands**, which are subject to DNA methylation. Hypermethylation of these CpG islands has been associated with reduced MTHFR expression in certain cancer cell lines, although the functional significance in normal tissues remains under investigation.
### 1.3 Enhancer Elements and Long-Range Regulation
Chromatin conformation capture studies (Hi-C and 3C) have identified several putative enhancer elements located in intronic regions and in intergenic sequences flanking the MTHFR gene. These enhancers interact with the promoter through chromatin looping, and their activity is modulated by histone modifications (H3K27ac and H3K4me1 marks). One notable enhancer region is located approximately 10 kb upstream of the transcription start site, which contains binding sites for **GATA transcription factors** and **C/EBP (CCAAT/Enhancer-Binding Protein)** , suggesting tissue-specific regulation in hematopoietic and hepatic lineages.
### 1.4 Alternative Splicing and Isoforms
Alternative splicing of MTHFR pre-mRNA generates multiple transcript variants. The primary transcript (NM_005957.5) encodes the canonical 656-amino acid protein. However, several alternatively spliced isoforms have been documented:
- **Isoform 2 (NM_001330358.2)**: Lacks exon 4, resulting in an in-frame deletion of 42 amino acids. This isoform retains catalytic activity but exhibits altered kinetic properties, with a reduced affinity for NADPH.
- **Isoform 3 (NM_001410836.1)**: Uses an alternative acceptor site in exon 8, producing a protein with a modified C-terminal regulatory domain.
- **Tissue-specific variants**: RNA-seq data from the Genotype-Tissue Expression (GTEx) project reveal differential isoform usage across tissues, with the brain and liver showing the highest diversity of MTHFR transcripts.
The biological significance of these isoforms is not fully characterized, but they may contribute to tissue-specific regulation of folate metabolism and differential responses to pharmacological interventions.
### 1.5 Regulatory Non-Coding RNAs
The MTHFR locus also hosts several long non-coding RNAs (lncRNAs) and is targeted by multiple microRNAs (miRNAs). Notably, **miR-34a** and **miR-449a** have been shown to bind the 3' UTR of MTHFR mRNA and downregulate its expression. These miRNAs are induced by p53, providing a link between DNA damage response pathways and folate metabolism. Additionally, the antisense transcript **MTHFR-AS1** has been identified, which may regulate MTHFR expression through transcriptional interference or RNA-RNA interactions.
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Overall Protein Topology
The MTHFR protein (UniProt P42898) is a **656-amino acid** flavoprotein that functions as a homodimer. Each monomer consists of two major functional domains connected by a flexible linker region:
1. **N-terminal Catalytic Domain (residues 1–356)**: This domain binds the substrates 5,10-methylenetetrahydrofolate and NADPH, and contains the non-covalently bound FAD cofactor. The domain adopts a **TIM-barrel (triosephosphate isomerase barrel)** fold, a common structural motif in enzymes that catalyze reactions involving nucleotide cofactors.
2. **C-terminal Regulatory Domain (residues 357–656)**: This domain contains the binding site for the allosteric inhibitor **S-adenosylmethionine (SAM)** . Binding of SAM induces a conformational change that reduces the enzyme's affinity for NADPH, providing feedback inhibition of the reaction.
The dimer interface is formed primarily by interactions between the C-terminal regulatory domains of the two monomers, although contacts between the catalytic domains also contribute to dimer stability.
### 2.2 Catalytic Site Architecture
The catalytic site is located in a deep cleft within the TIM-barrel domain. Key residues involved in substrate binding and catalysis include:
- **Arg157** and **Arg175**: Coordinate the phosphate groups of the folate substrate through electrostatic interactions.
- **Asp120** and **Glu123**: Participate in proton transfer during the reduction reaction.
- **Tyr73**: Forms a hydrogen bond with the pterin ring of the substrate, stabilizing the transition state.
- **Cys141**: Located near the FAD isoalloxazine ring, this residue is involved in electron transfer from NADPH to the substrate.
The FAD cofactor is deeply buried within the catalytic domain, with its isoalloxazine ring positioned at the base of the substrate-binding cleft. The adenine dinucleotide portion of FAD extends toward the protein surface, where it interacts with the NADPH binding site.
### 2.3 The C677T (Ala222Val) Variant
The C677T polymorphism results in a **alanine-to-valine substitution at position 222 (Ala222Val)** , located within the catalytic domain. This amino acid change occurs in a region of the protein that is in close proximity to the FAD binding pocket. Structural modeling and [molecular dynamics simulations](/knowledge/bioinformatics/molecular-dynamics-simulations-of-proteins-and-force-fields) indicate that the substitution of alanine (small, hydrophobic) with valine (larger, branched hydrophobic) introduces steric constraints that:
1. Reduce the thermal stability of the enzyme, leading to increased dissociation of the FAD cofactor.
2. Decrease the affinity for NADPH, impairing the enzyme's ability to regenerate the reduced FAD form.
3. Result in a **thermolabile** enzyme that loses activity more rapidly at physiological temperatures (37°C) compared to the wild-type protein.
The homozygous TT genotype is associated with approximately **30% of wild-type enzymatic activity**, while heterozygotes retain approximately **65% activity** [1][1][1][2].
### 2.4 The A1298C (Glu429Ala) Variant
The A1298C polymorphism causes a **glutamate-to-alanine substitution at position 429 (Glu429Ala)** , located in the C-terminal regulatory domain. This region is involved in SAM binding and dimerization. The substitution of a negatively charged, polar glutamate with a small, hydrophobic alanine:
1. Alters the conformation of the SAM binding pocket, potentially affecting the enzyme's sensitivity to allosteric inhibition.
2. May disrupt interactions at the dimer interface, affecting the stability of the homodimer.
3. Results in a moderate reduction in enzymatic activity, with the homozygous CC genotype associated with approximately **60% of wild-type activity**.
Importantly, the A1298C variant does not cause thermolability, and its effect on homocysteine levels is generally less pronounced than that of C677T [1][2][1][2].
### 2.5 Structural Consequences of Compound Heterozygosity
When an individual carries both the C677T and A1298C variants (compound heterozygosity), the resulting enzyme contains one monomer with the Ala222Val substitution and one with the Glu429Ala substitution. Biochemical studies suggest that compound heterozygotes have enzymatic activity levels comparable to C677T homozygotes, approximately 30–40% of wild-type. This is clinically significant, as compound heterozygosity has been associated with increased risk of thrombosis, recurrent pregnancy loss, and other hyperhomocysteinemia-related conditions [2][1][2][1][2].
### 2.6 Interactive 3D Visualization
[Interactive 3D Protein Visualizer: Load MTHFR (PDB: 6FCX)](/tools/protein-structure-viewer?source=direct&pdbId=6FCX)
The PDB entry 6FCX represents the crystal structure of human MTHFR in complex with FAD and SAM, solved at 2.8 Å resolution. This structure provides atomic-level detail of the enzyme's architecture, including the precise positioning of the C677T and A1298C variant residues within the three-dimensional fold. Users can explore the catalytic site, the FAD binding pocket, and the SAM regulatory domain using the interactive visualizer.
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 The Folate Cycle and One-Carbon Metabolism
MTHFR occupies a central position in the **folate-mediated one-carbon metabolism** pathway, which is compartmentalized between the cytoplasm, mitochondria, and nucleus. The enzyme catalyzes the following reaction:
**5,10-methylenetetrahydrofolate + NADPH + H⁺ → 5-methyltetrahydrofolate + NADP⁺**
This reaction is essentially irreversible under physiological conditions and commits folate to the methylation cycle rather than to DNA synthesis. The product, 5-methyltetrahydrofolate, serves as the methyl donor for the remethylation of homocysteine to methionine, a reaction catalyzed by **methionine synthase (MTR)** , which requires vitamin B12 as a cofactor.
### 3.2 The Transsulfuration and Remethylation Pathways
Homocysteine is a sulfur-containing amino acid that sits at a metabolic branch point:
1. **Remethylation pathway**: Homocysteine is converted back to methionine via the MTHFR-dependent folate cycle (as described above) or via the betaine-homocysteine methyltransferase (BHMT) pathway, which is primarily active in the liver and kidney.
2. **Transsulfuration pathway**: Homocysteine is irreversibly converted to cystathionine by **cystathionine β-synthase (CBS)** , requiring vitamin B6 as a cofactor. Cystathionine is subsequently cleaved to cysteine, which is a precursor for glutathione synthesis.
When MTHFR activity is reduced, the remethylation pathway is impaired, leading to accumulation of homocysteine. Elevated homocysteine levels (hyperhomocysteinemia) are associated with endothelial dysfunction, oxidative stress, and increased risk of thrombotic events [1][2][1][1].
### 3.3 Regulation of MTHFR Activity
MTHFR activity is regulated at multiple levels:
**Allosteric Regulation**: SAM acts as a potent allosteric inhibitor of MTHFR. When cellular SAM levels are high, MTHFR is inhibited, reducing the production of 5-methyltetrahydrofolate and directing folate toward DNA synthesis. Conversely, when SAM levels are low, MTHFR is activated, promoting homocysteine remethylation and methionine production.
**Phosphorylation**: MTHFR is phosphorylated at multiple serine residues by **AMP-activated protein kinase (AMPK)** . Phosphorylation increases the enzyme's sensitivity to SAM inhibition, providing a mechanism for energy status to modulate folate metabolism.
**Transcriptional Regulation**: MTHFR expression is regulated by transcription factors including Sp1, CREB, and NF-κB, as discussed in Section 1.2. Additionally, the transcription factor **Nrf2 (Nuclear factor erythroid 2-related factor 2)** , a master regulator of antioxidant responses, has been shown to bind the MTHFR promoter and upregulate its expression under conditions of oxidative stress.
### 3.4 Protein-Protein Interaction Networks
MTHFR interacts with several proteins involved in one-carbon metabolism and cellular stress responses. Key interactions identified through yeast two-hybrid screens, co-immunoprecipitation, and proximity labeling include:
| **Interacting Protein** | **Function** | **Interaction Type** |
|---|---|---|
| **MTR (Methionine Synthase)** | Remethylation of homocysteine | Substrate channeling; MTHFR product is the substrate for MTR |
| **MTRR (Methionine Synthase Reductase)** | Regeneration of active MTR | Functional coupling; MTRR maintains MTR in its active state |
| **SHMT1 (Serine Hydroxymethyltransferase 1)** | Generates 5,10-methylenetetrahydrofolate | Substrate supply; SHMT1 produces the substrate for MTHFR |
| **TYMS (Thymidylate Synthase)** | DNA synthesis | Metabolic competition; both enzymes use 5,10-methylenetetrahydrofolate |
| **DHFR (Dihydrofolate Reductase)** | Folate recycling | Metabolic coupling |
| **p53 (Tumor Protein p53)** | DNA damage response | Transcriptional regulation; p53 induces miRNAs that target MTHFR |
| **AMPK (AMP-Activated Protein Kinase)** | Energy sensing | Post-translational modification; AMPK phosphorylates MTHFR |
### 3.5 MTHFR in Epigenetic Regulation
The product of the MTHFR reaction, 5-methyltetrahydrofolate, is essential for the synthesis of SAM, the universal methyl donor for DNA and histone methylation. Reduced MTHFR activity leads to decreased SAM levels and increased SAH (S-adenosylhomocysteine) levels, which is a potent inhibitor of methyltransferases. This can result in:
- **Global DNA hypomethylation**: Reduced methylation of CpG islands throughout the genome, potentially leading to genomic instability and aberrant gene expression.
- **Promoter-specific hypermethylation**: Paradoxically, some gene promoters may become hypermethylated, leading to silencing of tumor suppressor genes.
- **Altered histone methylation patterns**: Changes in histone marks (e.g., H3K4me3, H3K9me3) that affect chromatin structure and gene expression.
These epigenetic effects are particularly relevant in cancer, where MTHFR polymorphisms have been associated with altered risk and prognosis [2][1][2][1][2][1].
### 3.6 MTHFR and Neurotransmitter Synthesis
MTHFR activity influences the synthesis of several neurotransmitters through its effects on the methylation cycle:
- **Dopamine and Norepinephrine**: SAM is required for the methylation of catecholamines. Reduced SAM levels can impair catecholamine metabolism.
- **Serotonin**: Folate deficiency and hyperhomocysteinemia have been associated with altered serotonin metabolism.
- **Nitric Oxide (NO)**: Hyperhomocysteinemia can lead to endothelial dysfunction and reduced NO bioavailability, affecting cerebral blood flow.
These mechanisms may explain the associations between MTHFR polymorphisms and neuropsychiatric conditions, including migraine with aura [2][2], depression [1], and obsessive-compulsive disorder [2].
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 The C677T Polymorphism (rs1801133)
**Nucleotide Change**: c.665C>T (historically designated c.677C>T)
**Amino Acid Change**: p.Ala222Val
**Location**: Exon 4, catalytic domain
**Minor Allele Frequency**: Highly variable by population; ~30–40% in Europeans, ~10–20% in Africans, ~40–50% in some Asian populations [1][2][1][2][1]
**Enzymatic Consequences**:
- Thermolabile enzyme variant
- Reduced FAD binding affinity
- Decreased NADPH utilization
- Homozygous TT: ~30% residual activity
- Heterozygous CT: ~65% residual activity
**Clinical Associations**:
- **Hyperhomocysteinemia**: The TT genotype is consistently associated with elevated plasma homocysteine levels, particularly under conditions of low folate status [1][2][1][2].
- **Venous Thromboembolism (VTE)**: Meta-analyses have shown a modest but significant association between the TT genotype and VTE risk, particularly in combination with other thrombophilic risk factors [2][1][1][2].
- **Recurrent Pregnancy Loss (RPL)**: Multiple studies have demonstrated an increased frequency of the TT genotype in women with RPL, likely mediated through placental thrombosis and insufficiency [2][1][2][1][2][1][2][1].
- **Neural Tube Defects (NTDs)**: The TT genotype is associated with increased risk of NTDs, particularly in offspring of mothers with low folate intake [1][2].
- **Cardiovascular Disease**: Associations with coronary artery disease, stroke, and hypertension have been reported, though results are heterogeneous across populations [2][1][2][1][2].
- **Diabetic Nephropathy**: The TT genotype has been associated with increased risk of nephropathy in type 2 diabetes patients [1][2][2].
- **Cancer Risk**: The TT genotype has been associated with altered risk for various cancers, including colorectal, breast, and lung cancer, with effects dependent on folate status [2][1][1][2][1][1].
- **Migraine with Aura**: The TT genotype is associated with increased risk of migraine with aura, particularly in women [2][2].
- **Parkinson's Disease**: The C677T polymorphism may modify age at onset in Parkinson's disease [2].
### 4.2 The A1298C Polymorphism (rs1801131)
**Nucleotide Change**: c.1286A>C (historically designated c.1298A>C)
**Amino Acid Change**: p.Glu429Ala
**Location**: Exon 7, regulatory domain
**Minor Allele Frequency**: ~30–40% in most populations; higher in some Mediterranean and Middle Eastern populations [1][2][1][2][1][1]
**Enzymatic Consequences**:
- Moderate reduction in enzymatic activity (~60% residual in CC homozygotes)
- No thermolability
- Altered SAM binding and dimer stability
**Clinical Associations**:
- **Hyperhomocysteinemia**: The effect of A1298C on homocysteine levels is generally weaker than C677T, and some studies report no significant association [1][2][2].
- **Venous Thromboembolism**: The CC genotype has been associated with increased VTE risk in some populations, particularly in combination with C677T [2][1][1].
- **Recurrent Pregnancy Loss**: Associations with RPL have been reported, though less consistently than for C677T [1][1][2][2][1].
- **Neural Tube Defects**: Some studies suggest an association between A1298C and NTD risk, though findings are inconsistent [1][2].
- **Diabetic Nephropathy**: The CC genotype has been associated with increased risk of nephropathy in type 2 diabetes [1][2][2].
- **Sickle Cell Disease**: The A1298C polymorphism has been associated with altered disease severity in sickle cell disease [2].
- **Renal Function Decline**: The A1298C polymorphism predicts decline in renal function in African-American patients with hypertension [1].
- **Non-Obstructive Azoospermia**: The A1298C polymorphism has been associated with increased risk of non-obstructive azoospermia in Bulgarian patients [2].
- **Polycystic Ovary Syndrome (PCOS)**: Associations with PCOS risk have been reported in Southern Chinese women [1].
### 4.3 Compound Heterozygosity (C677T + A1298C)
Compound heterozygotes (carrying one C677T allele and one A1298C allele) represent a clinically important genotype. The combined effect on enzymatic activity is approximately 30–40% of wild-type, similar to C677T homozygotes. However, the clinical phenotype may differ due to the distinct structural consequences of each variant.
**Clinical Associations**:
- **Recurrent Thrombotic Events**: Compound heterozygosity has been associated with recurrent venous and arterial thrombotic events, particularly in young patients [2][1].
- **Recurrent Pregnancy Loss**: Compound heterozygosity is associated with increased risk of RPL, particularly when combined with other thrombophilic mutations [2][2][1][2][1].
- **Abruptio Placentae**: Combined heterozygosity has been specifically associated with abruptio placentae [2].
- **Neural Tube Defects**: Compound heterozygosity may increase NTD risk, particularly in populations with low folate intake [1][2].
- **Cardiovascular Disease**: Compound heterozygosity has been associated with increased risk of coronary artery disease and stroke [2][1][2][2].
- **Buerger's Disease**: Compound heterozygosity, combined with smoking, has been associated with increased risk of Buerger's disease [2][1].
- **Antiphospholipid Antibody Syndrome**: Compound heterozygosity has been reported in patients with antiphospholipid syndrome and hyperhomocysteinemia [2].
### 4.4 Rare Pathogenic Mutations
Beyond the common polymorphisms, rare mutations in MTHFR can cause **severe MTHFR deficiency** (OMIM #236250), an autosomal recessive inborn error of metabolism characterized by:
- Homocystinuria
- Hypomethioninemia
- Neurological abnormalities (seizures, developmental delay, microcephaly)
- Vascular complications (thrombosis, atherosclerosis)
- Ocular abnormalities (ectopia lentis, myopia)
More than 40 rare mutations have been described, including missense, nonsense, frameshift, and splice-site mutations. These mutations typically result in near-complete loss of enzymatic activity and present in infancy or early childhood.
### 4.5 Diagnostic Considerations and Clinical Testing
**Indications for MTHFR Genetic Testing**:
- Unexplained hyperhomocysteinemia
- Recurrent venous or arterial thrombosis, particularly in young patients
- Recurrent pregnancy loss
- Family history of MTHFR deficiency
- Assessment of thrombophilia risk in high-risk populations
**Testing Methods**:
- **PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism)**: The traditional method for detecting C677T and A1298C variants. The C677T mutation creates an HinfI restriction site, while the A1298C mutation abolishes an MboII restriction site [1][1][2].
- **ARMS-PCR (Amplification Refractory Mutation System-PCR)**: A more rapid and cost-effective method that uses allele-specific primers [1].
- **Real-Time PCR with TaqMan probes**: High-throughput method suitable for clinical laboratories.
- **Sanger Sequencing**: Gold standard for confirmation and detection of rare mutations.
- **Next-Generation Sequencing (NGS)**: Allows simultaneous analysis of multiple thrombophilia genes.
**Interpretation Caveats**:
- The clinical significance of C677T and A1298C variants is controversial, and routine screening is not recommended by most professional societies.
- The presence of MTHFR variants should be interpreted in the context of plasma homocysteine levels, folate status, and other thrombophilic risk factors [1].
- Normal homocysteine levels do not exclude the possibility of MTHFR-related thrombotic risk [2].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 MTHFR and Hepatitis B Virus (HBV)
Chronic hepatitis B virus (HBV) infection is a major global health burden, and host genetic factors influence disease progression. A study by Qiu et al. (2024) investigated the interrelationships among MTHFR gene polymorphisms, MTRR gene polymorphisms, and HBV gene BCP 1762/1764 mutations with disease progression in chronic HBV infection patients [2]. The study found that:
- MTHFR C677T and A1298C polymorphisms were associated with altered risk of HBV-related liver disease progression.
- The combination of MTHFR variants with HBV BCP mutations was associated with more severe liver damage.
- These effects may be mediated through altered folate metabolism affecting immune function and liver regeneration.
### 5.2 MTHFR and COVID-19
The COVID-19 pandemic has highlighted the importance of thrombotic complications in infectious diseases. Several studies have investigated the relationship between MTHFR mutations and COVID-19 severity:
- Moness et al. (2024) found that thrombophilia genetic mutations, including MTHFR C677T and A1298C, were associated with disease severity in COVID-19 patients [1].
- A short review by an anonymous author (2020) suggested possible links between MTHFR mutations, homocysteinemia, and metabolic disturbances in COVID-19 [2].
- The proposed mechanisms include:
- Hyperhomocysteinemia-induced endothelial dysfunction
- Increased thrombotic risk in patients with pre-existing MTHFR variants
- Altered immune responses due to impaired methylation capacity
### 5.3 MTHFR and Other Pathogens
The relationship between MTHFR and infectious diseases extends beyond HBV and SARS-CoV-2:
- **Malaria**: A study by Falchi et al. (2006) proposed that MTHFR polymorphisms may have been subject to genetic selection from malaria, potentially explaining the high frequency of these variants in Mediterranean populations [1].
- **Human Papillomavirus (HPV)**: Folate metabolism and MTHFR variants may influence HPV persistence and progression to cervical cancer, though direct evidence is limited.
- **Helicobacter pylori**: H. pylori infection can lead to folate deficiency, which may interact with MTHFR variants to increase gastric cancer risk.
### 5.4 Mechanistic Insights
The interaction between MTHFR and pathogens likely involves several mechanisms:
1. **Folate Sequestration**: Some pathogens, including Plasmodium species, require host folate for survival and may deplete host folate stores, exacerbating the effects of MTHFR variants.
2. **Immune Modulation**: Folate metabolism is critical for immune cell proliferation and function. Reduced MTHFR activity may impair T-cell responses and antibody production.
3. **Thrombotic Complications**: Many infections, particularly COVID-19, are associated with increased thrombotic risk. Pre-existing MTHFR variants may compound this risk through hyperhomocysteinemia.
4. **Epigenetic Effects**: Pathogen-induced changes in host DNA methylation may interact with MTHFR variants to alter gene expression patterns.
---
## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors
### 6.1 Folate Supplementation and L-Methylfolate
The most direct pharmacological intervention for MTHFR-related disorders is **folate supplementation**. However, the form of folate is critical:
- **Folic Acid (Pteroylglutamic Acid)**: The synthetic form used in supplements and food fortification. Folic acid requires reduction by **dihydrofolate reductase (DHFR)** to become biologically active. In individuals with MTHFR variants, the downstream conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate is impaired, limiting the effectiveness of folic acid supplementation.
- **L-Methylfolate (5-Methyltetrahydrofolate)**: The active form of folate that bypasses the MTHFR reaction. L-methylfolate supplementation has been shown to be more effective than folic acid in reducing homocysteine levels in individuals with MTHFR variants [1].
- **Folinic Acid (Leucovorin)**: A reduced folate that can be converted to 5-methyltetrahydrofolate without requiring DHFR, but still requires MTHFR for the final step.
**Clinical Applications**:
- **Depression**: L-methylfolate has been shown to improve depressive symptoms in patients with MTHFR mutations, particularly those with the C677T TT genotype [1].
- **Cardiovascular Risk Reduction**: Folate supplementation, particularly with L-methylfolate, can reduce homocysteine levels and potentially reduce cardiovascular risk.
- **Pregnancy**: High-dose folic acid (4–5 mg/day) is recommended for women with MTHFR variants and a history of neural tube defects or recurrent pregnancy loss.
### 6.2 B-Vitamin Cofactors
**Vitamin B12 (Cobalamin)**: Required as a cofactor for methionine synthase, which uses 5-methyltetrahydrofolate to remethylate homocysteine. Vitamin B12 supplementation can partially compensate for reduced MTHFR activity.
**Vitamin B6 (Pyridoxine)**: Required for the transsulfuration pathway enzyme cystathionine β-synthase. Vitamin B6 supplementation can promote homocysteine clearance through the transsulfuration pathway, bypassing the MTHFR-dependent remethylation pathway.
**Riboflavin (Vitamin B2)**: As a precursor to FAD, riboflavin supplementation may stabilize the MTHFR enzyme and improve its activity, particularly in individuals with the C677T variant.
**Betaine (Trimethylglycine)**: Serves as an alternative methyl donor for homocysteine remethylation via the BHMT pathway. Betaine supplementation can reduce homocysteine levels independent of MTHFR activity.
### 6.3 Anticoagulant and Antiplatelet Therapy
For individuals with MTHFR variants and thrombotic events, standard anticoagulant therapy is indicated:
- **Low-Molecular-Weight Heparin (LMWH)**: Used for acute thrombotic events and during pregnancy in women with MTHFR variants and a history of thrombosis.
- **Warfarin**: Vitamin K antagonist used for long-term anticoagulation.
- **Direct Oral Anticoagulants (DOACs)**: Including rivaroxaban, apixaban, and dabigatran, which are increasingly used for VTE treatment and prevention.
- **Aspirin**: Low-dose aspirin may be recommended for primary prevention in high-risk individuals.
### 6.4 Methotrexate and MTHFR [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles)
**Methotrexate (MTX)** is a folate antagonist used in the treatment of cancer, rheumatoid arthritis, and other autoimmune diseases. MTX inhibits **dihydrofolate reductase (DHFR)** , depleting the intracellular folate pool. MTHFR variants may influence MTX efficacy and toxicity:
- **C677T TT genotype**: Associated with increased MTX toxicity (hepatotoxicity, myelosuppression, mucositis) and reduced efficacy in some studies.
- **A1298C CC genotype**: May also influence MTX response, though findings are less consistent.
- **Clinical Implications**: MTHFR genotyping may guide MTX dosing and monitoring, though routine testing is not universally recommended [2].
### 6.5 Investigational Therapies
**Gene Therapy**: Preclinical studies are exploring the use of adeno-associated virus (AAV) vectors to deliver functional MTHFR cDNA to patients with severe MTHFR deficiency. While no clinical trials are currently underway, this approach holds promise for the treatment of this rare disorder.
**Small-Molecule Chaperones**: Compounds that stabilize the MTHFR protein and prevent FAD dissociation are being investigated as potential therapies for C677T-associated thermolability.
**SAMe (S-Adenosylmethionine)**: SAMe supplementation may bypass the methylation cycle defect by providing a direct source of methyl groups. However, its efficacy in MTHFR deficiency is not well established.
### 6.6 Drug Interactions
Several drugs can affect folate metabolism and interact with MTHFR variants:
- **Anticonvulsants** (phenytoin, carbamazepine, valproic acid): Can cause folate deficiency.
- **Sulfasalazine**: Inhibits folate absorption.
- **Triamterene**: A diuretic that inhibits DHFR.
- **Trimethoprim**: An antibiotic that inhibits DHFR.
- **Nitrous Oxide**: Inactivates methionine synthase, exacerbating the effects of MTHFR variants.
---
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| **NCBI Gene** | 4524 | Gene-specific information, genomic context, and links to related resources |
| **Ensembl** | ENSG00000177000 | Genome annotation, transcripts, and variation data |
| **UniProt** | P42898 | Protein sequence, function, and post-translational modifications |
| **RCSB PDB** | 6FCX | Experimentally determined 3D structure |
| **OMIM** | 607093 | Gene description and associated phenotypes |
| **ClinVar** | Multiple entries | Clinical significance of variants |
| **dbSNP** | rs1801133 (C677T), rs1801131 (A1298C) | Single nucleotide polymorphism data |
| **Gene Ontology (GO)** | GO:0004489 (methylenetetrahydrofolate reductase activity), GO:0005737 (cytoplasm), GO:0005829 (cytosol) | Molecular function, cellular component, biological process |
| **STRING** | P42898 | Protein-protein interaction networks |
| **BioGRID** | 112345 | Protein interaction data |
| **PharmGKB** | PA315 | Pharmacogenomic information |
| **GTEx** | MTHFR | Tissue-specific gene expression data |
| **Human Protein Atlas** | ENSG00000177000 | Protein expression and localization data |
---
## Related Clinical & Scientific Guides
* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)
## References
[1] Ramaji, G. A., & Nazemi, A. (2020). Development of ARMS-PCR method to detect two mutations of MTHFR gene(C677T,A1298C)in suspected cases of thrombosis. https://www.semanticscholar.org/paper/74bd3ef5c6d2f8a8a23e44995521819ca38b4e80
[2] Aliyeva, J. T., Qurbanova, J., Aliyeva, K., & Azadova, A. (2025). THE RELATIONSHIP BETWEEN MTHFR GENE MUTATIONS AND TWO OR MORE RECURRENT PREGNANCY LOSSES. Proceedings of the Institute of Genetic Resources of the Ministry of Science and Education Republic of Azerbaijan. https://www.semanticscholar.org/paper/a5be42c